Alison F. Hinckley

Alison F. Hinckley

Auto-generated profile, based on publicly available information

Alison F. Hinckley

Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAlison F. Hinckley
Alison F. Hinckley
NCNeeta P. Connally
Neeta P. Connally
JMJames I. Meek
James I. Meek
BJBarbara J. Johnson
Barbara J. Johnson
MKMelissa M. Kemperman
Melissa M. Kemperman
PMPaul S. Mead
Paul S. Mead
Large commercial laboratories in the United States were surveyed to determine Lyme disease testing frequency, practices, and results. Approximately 3.4 million tests were conducted in 2008; 62% in accordance with recommendations. We estimate that 288 000 infections occurred among 2.4 million patients from whom samples were submitted. Background. Laboratory testing is helpful when evaluating patients with suspected Lyme disease (LD). A 2-tiered antibody testing approach is recommended, but single-tier and nonvalidated tests are also used. We conducted a survey of large commercial laboratories in the United States to assess laboratory practices. We used these data to estimate the cost of testing and number of infections among patients from whom specimens were submitted. Methods. Large commercial laboratories were asked to report the type and volume of testing conducted nationwide in 2008, as well as the percentage of positive tests for 4 LD-endemic states. The total direct cost of testing was calculated for each test type. These data and test-specific performance parameters available in published literature were used to estimate the number of infections among source patients. Results. Seven participating laboratories performed approximately 3.4 million LD tests on approximately 2.4 million specimens nationwide at an estimated cost of $492 million. Two-tiered testing accounted for at least 62% of assays performed; alternative testing accounted for <3% of assays. The estimated frequency of infection among patients from whom specimens were submitted ranged from 10% to 18.5%. Applied to the total numbers of specimens, this yielded an estimated 240 000 to 444 000 infected source patients in 2008. Discussion. LD testing is common and costly, with most testing in accordance with diagnostic recommendations. These results highlight the importance of considering clinical and exposure history when interpreting laboratory results for diagnostic and surveillance purposes.

1 January 2021 in Emerging Infectious Diseases
Verified
Journal Article
Closed access
ASAmy M. Schwartz
Amy M. Schwartz
KKKiersten J. Kugeler
Kiersten J. Kugeler
CNChristina A. Nelson
Christina A. Nelson
GMGrace E. Marx
Grace E. Marx
AHAlison F. Hinckley
Alison F. Hinckley
Claims Data for Evaluating Lyme Disease Diagnosis

1 March 2007 in Pediatrics
Verified
Journal Article
Closed access
AHAlison F. Hinckley
Alison F. Hinckley
DODaniel R. O'LEary
Daniel R. O'LEary
EHEdward B. Hayes
Edward B. Hayes
INTRODUCTION.In September 2002, possible transmission of West Nile virus via human milk was reported for the first time. METHODS.Since 2003, the Centers for Disease Control and Prevention collected reports of maternal or infant West Nile virus illness during the breastfeeding period. All of the reported instances were reviewed. In addition, milk samples from women infected during pregnancy were tested for West Nile virus RNA and West Nile virus–specific antibodies. RESULTS.Six infants were reported to have breastfed from mothers with West Nile virus fever. Five of the 6 infants had no illness or detectable antibodies to West Nile virus in serum after onset of maternal illness. One infant who was not tested and developed a rash was otherwise well 1 week after onset of maternal illness. In addition, 2 infants were reported to have developed West Nile virus illness while breastfeeding; preceding maternal illness was not documented. Two breastfed infants whose mothers acquired West Nile virus fever in the last week of pregnancy developed West Nile virus–specific antibodies; both infant infections could have been congenitally acquired. Of 45 milk samples from women infected with West Nile virus during pregnancy, 2 had West Nile virus RNA, and 14 had immunoglobin M antibodies to West Nile virus. CONCLUSIONS.Of 10 reported instances since 2003 of maternal or infant West Nile virus illness while breastfeeding, transmission of West Nile virus through human milk could neither be ruled out nor confirmed for 5 cases; in 5 others, serologic tests indicated no vertical transmission. Transmission of West Nile virus through breastfeeding seems to be rare, but more information is needed.

1 December 2005 in Environmental Health Perspectives
Verified
Journal Article
Open access
AHAlison F. Hinckley
Alison F. Hinckley
ABAnnette M. Bachand
Annette M. Bachand
JRJohn S. Reif
John S. Reif
Toxicologic studies have demonstrated associations between growth-related birth outcomes and exposure to high concentrations of disinfection by-products (DBPs), including specific tri-halomethane (THM) and haloacetic acid (HAA) chemical subspecies. Few ...

5 January 2016 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAlison F. Hinckley
Alison F. Hinckley
JMJames I. Meek
James I. Meek
JRJulie A. E. Ray
Julie A. E. Ray
SNSara A. Niesobecki
Sara A. Niesobecki
NCNeeta P. Connally
Neeta P. Connally
PMPaul S. Mead
Paul S. Mead
Background. In the northeastern United States, tick-borne diseases are a major public health concern. In controlled studies, a single springtime application of acaricide has been shown to kill 68%–100% of ticks. Although public health authorities recommend use of acaricides to control tick populations in yards, the effectiveness of these pesticides to prevent tick bites or human tick-borne diseases is unknown. Methods. We conducted a 2-year, randomized, double-blinded, placebo-controlled trial among 2727 households in 3 northeastern states. Households received a single springtime barrier application of bifenthrin or water according to recommended practices. Tick drags were conducted 3–4 weeks after treatment on 10% of properties. Information on human–tick encounters and tick-borne diseases was collected through monthly surveys; reports of illness were validated by medical record review. Results. Although the abundance of questing ticks was significantly lower (63%) on acaricide-treated properties, there was no difference between treatment groups in human-tick encounters, self-reported tick-borne diseases, or medical-record-validated tick-borne diseases. Conclusions. Used as recommended, acaricide barrier sprays do not significantly reduce the household risk of tick exposure or incidence of tick-borne disease. Measures for preventing tick-borne diseases should be evaluated against human outcomes to confirm effectiveness.

1 October 2019 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
SNSara Niesobecki
Sara Niesobecki
AHAmberJean Hansen
AmberJean Hansen
HRHeather Rutz
Heather Rutz
SMShaylee Mehta
Shaylee Mehta
KFKatherine Feldman
Katherine Feldman
AHAlison Hinckley
Alison Hinckley